vs
Side-by-side financial comparison of Everus Construction Group, Inc. (ECG) and QuidelOrtho Corp (QDEL). Click either name above to swap in a different company.
Everus Construction Group, Inc. is the larger business by last-quarter revenue ($1.0B vs $699.9M, roughly 1.4× QuidelOrtho Corp). Everus Construction Group, Inc. runs the higher net margin — 5.5% vs -104.7%, a 110.2% gap on every dollar of revenue. On growth, Everus Construction Group, Inc. posted the faster year-over-year revenue change (33.2% vs -3.7%). Everus Construction Group, Inc. produced more free cash flow last quarter ($23.5M vs $-94.7M). Over the past eight quarters, Everus Construction Group, Inc.'s revenue compounded faster (27.1% CAGR vs -2.9%).
QuidelOrtho Corporation is an American manufacturer of diagnostic healthcare products that are sold worldwide.
ECG vs QDEL — Head-to-Head
Income Statement — Q4 FY2025 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $1.0B | $699.9M |
| Net Profit | $55.3M | $-733.0M |
| Gross Margin | 11.6% | — |
| Operating Margin | 6.8% | -100.7% |
| Net Margin | 5.5% | -104.7% |
| Revenue YoY | 33.2% | -3.7% |
| Net Profit YoY | 60.4% | -3583.4% |
| EPS (diluted) | $1.09 | $-10.78 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $1.0B | — | ||
| Q3 25 | $986.8M | $699.9M | ||
| Q2 25 | $921.5M | $613.9M | ||
| Q1 25 | $826.6M | $692.8M | ||
| Q4 24 | $759.6M | $707.8M | ||
| Q3 24 | $761.0M | $727.1M | ||
| Q2 24 | $703.4M | $637.0M | ||
| Q1 24 | $625.7M | $711.0M |
| Q4 25 | $55.3M | — | ||
| Q3 25 | $57.0M | $-733.0M | ||
| Q2 25 | $52.8M | $-255.4M | ||
| Q1 25 | $36.7M | $-12.7M | ||
| Q4 24 | $34.5M | $-178.4M | ||
| Q3 24 | $41.8M | $-19.9M | ||
| Q2 24 | $39.0M | $-147.7M | ||
| Q1 24 | $28.2M | $-1.7B |
| Q4 25 | 11.6% | — | ||
| Q3 25 | 12.6% | — | ||
| Q2 25 | 13.0% | — | ||
| Q1 25 | 11.2% | — | ||
| Q4 24 | 11.4% | — | ||
| Q3 24 | 11.8% | — | ||
| Q2 24 | 12.6% | — | ||
| Q1 24 | 11.9% | — |
| Q4 25 | 6.8% | — | ||
| Q3 25 | 7.3% | -100.7% | ||
| Q2 25 | 7.9% | -29.4% | ||
| Q1 25 | 6.2% | 4.7% | ||
| Q4 24 | 6.1% | -14.2% | ||
| Q3 24 | 7.1% | 2.1% | ||
| Q2 24 | 7.3% | -18.4% | ||
| Q1 24 | 6.2% | -247.3% |
| Q4 25 | 5.5% | — | ||
| Q3 25 | 5.8% | -104.7% | ||
| Q2 25 | 5.7% | -41.6% | ||
| Q1 25 | 4.4% | -1.8% | ||
| Q4 24 | 4.5% | -25.2% | ||
| Q3 24 | 5.5% | -2.7% | ||
| Q2 24 | 5.5% | -23.2% | ||
| Q1 24 | 4.5% | -239.9% |
| Q4 25 | $1.09 | — | ||
| Q3 25 | $1.11 | $-10.78 | ||
| Q2 25 | $1.03 | $-3.77 | ||
| Q1 25 | $0.72 | $-0.19 | ||
| Q4 24 | $0.68 | $-2.54 | ||
| Q3 24 | $0.82 | $-0.30 | ||
| Q2 24 | $0.76 | $-2.20 | ||
| Q1 24 | $0.55 | $-25.50 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $98.1M |
| Total DebtLower is stronger | $281.5M | $2.5B |
| Stockholders' EquityBook value | $629.8M | $2.0B |
| Total Assets | $1.7B | $5.7B |
| Debt / EquityLower = less leverage | 0.45× | 1.23× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | — | ||
| Q3 25 | — | $98.1M | ||
| Q2 25 | — | $151.7M | ||
| Q1 25 | — | $127.1M | ||
| Q4 24 | — | $98.3M | ||
| Q3 24 | $553.0K | $143.7M | ||
| Q2 24 | — | $107.0M | ||
| Q1 24 | — | $78.5M |
| Q4 25 | $281.5M | — | ||
| Q3 25 | $285.1M | $2.5B | ||
| Q2 25 | $288.6M | $2.1B | ||
| Q1 25 | $292.1M | $2.1B | ||
| Q4 24 | $295.6M | $2.1B | ||
| Q3 24 | — | $2.2B | ||
| Q2 24 | — | $2.2B | ||
| Q1 24 | — | $2.2B |
| Q4 25 | $629.8M | — | ||
| Q3 25 | $573.0M | $2.0B | ||
| Q2 25 | $514.4M | $2.8B | ||
| Q1 25 | $460.2M | $3.0B | ||
| Q4 24 | $422.6M | $3.0B | ||
| Q3 24 | $453.3M | $3.2B | ||
| Q2 24 | $490.0M | $3.2B | ||
| Q1 24 | $464.3M | $3.3B |
| Q4 25 | $1.7B | — | ||
| Q3 25 | $1.6B | $5.7B | ||
| Q2 25 | $1.5B | $6.4B | ||
| Q1 25 | $1.4B | $6.5B | ||
| Q4 24 | $1.3B | $6.4B | ||
| Q3 24 | $1.3B | $6.8B | ||
| Q2 24 | — | $6.7B | ||
| Q1 24 | — | $6.7B |
| Q4 25 | 0.45× | — | ||
| Q3 25 | 0.50× | 1.23× | ||
| Q2 25 | 0.56× | 0.74× | ||
| Q1 25 | 0.63× | 0.70× | ||
| Q4 24 | 0.70× | 0.72× | ||
| Q3 24 | — | 0.68× | ||
| Q2 24 | — | 0.70× | ||
| Q1 24 | — | 0.68× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $48.2M | $-45.5M |
| Free Cash FlowOCF − Capex | $23.5M | $-94.7M |
| FCF MarginFCF / Revenue | 2.3% | -13.5% |
| Capex IntensityCapex / Revenue | 2.4% | 7.0% |
| Cash ConversionOCF / Net Profit | 0.87× | — |
| TTM Free Cash FlowTrailing 4 quarters | $90.0M | $-153.1M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $48.2M | — | ||
| Q3 25 | $76.2M | $-45.5M | ||
| Q2 25 | $25.3M | $-46.8M | ||
| Q1 25 | $7.1M | $65.6M | ||
| Q4 24 | — | $63.7M | ||
| Q3 24 | $78.9M | $117.9M | ||
| Q2 24 | — | $-97.9M | ||
| Q1 24 | $21.9M | $-700.0K |
| Q4 25 | $23.5M | — | ||
| Q3 25 | $65.7M | $-94.7M | ||
| Q2 25 | $12.3M | $-84.3M | ||
| Q1 25 | $-11.4M | $9.4M | ||
| Q4 24 | — | $16.5M | ||
| Q3 24 | $60.9M | $71.4M | ||
| Q2 24 | — | $-133.2M | ||
| Q1 24 | $12.6M | $-66.8M |
| Q4 25 | 2.3% | — | ||
| Q3 25 | 6.7% | -13.5% | ||
| Q2 25 | 1.3% | -13.7% | ||
| Q1 25 | -1.4% | 1.4% | ||
| Q4 24 | — | 2.3% | ||
| Q3 24 | 8.0% | 9.8% | ||
| Q2 24 | — | -20.9% | ||
| Q1 24 | 2.0% | -9.4% |
| Q4 25 | 2.4% | — | ||
| Q3 25 | 1.1% | 7.0% | ||
| Q2 25 | 1.4% | 6.1% | ||
| Q1 25 | 2.2% | 8.1% | ||
| Q4 24 | — | 6.7% | ||
| Q3 24 | 2.4% | 6.4% | ||
| Q2 24 | — | 5.5% | ||
| Q1 24 | 1.5% | 9.3% |
| Q4 25 | 0.87× | — | ||
| Q3 25 | 1.34× | — | ||
| Q2 25 | 0.48× | — | ||
| Q1 25 | 0.19× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 1.89× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 0.77× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ECG
| Commercial | $594.5M | 59% |
| Utility | $203.5M | 20% |
| Industrial | $82.8M | 8% |
| Institutional | $66.1M | 7% |
| Service And Other | $28.4M | 3% |
| Transportation | $24.2M | 2% |
| Renewables | $19.8M | 2% |
QDEL
| Labs | $373.8M | 53% |
| Point Of Care | $164.6M | 24% |
| Immunohematology | $142.0M | 20% |
| Donor Screening | $14.7M | 2% |
| Molecular Diagnostics | $4.8M | 1% |
| Collaborative Arrangement Transaction With Party To Collaborative Arrangement | $2.1M | 0% |
